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Nuclease StrategiesGenome editing technologies based on RNA-
guided nucleases (RGNs) derived from
prokaryotic type II CRISPR-Cas9 adaptive
immune systems, such as that from Strepto-
coccus pyogenes1,2 and, more recently, Staph-
ylococcus aureus,3,4 are becoming increas-
ingly pervasive in both basic and applied
research.5,6 RGNs are ribonucleoprotein
complexes whose sequence-specific guide
RNA (gRNA) moieties address a Cas9
nuclease to a DNA target site (Figure S1A).
Base pairing between the 50-terminal nucleo-
tides of the gRNA (spacer) and DNA se-
quences connected to a protospacer-adjacent
motif (PAM), triggers Cas9-mediated dou-
ble-stranded DNA break (DSB) formation.5,6
RGNs based on S. pyogenes Cas9 (SpCas9)
and on S. aureus Cas9 (SaCas9) typically
have spacers with a length of 20 and 21–24
nucleotides, respectively. The PAMof SpCas9
is NGG, while that of SaCas9 is NNGRRT.3,6
The repair of RGN-induced targeted DNA
lesions by non-homologous end joining
(NHEJ) or homologous recombination can
result in either the deletion or addition of ge-
netic information in cells from virtually any
organism.5,6
Despite their ease of use and broad applica-
bility, a major limitation of conventional
RGNs is that of off-target DNA cleavage.
Indeed, it has been demonstrated that up to
five gRNA-DNA mismatches can be toler-
ated, especially when located most distally
to the PAM.7 Such mismatches can conceiv-
ably result in several hundreds of DSBs
across the genome.7 Therefore, substantial
efforts have been made in recent years to
minimize RGN off-target activities. These
efforts resulted in a set of improved genome
editing strategies, of which preeminent
examples include: (1) RGNs harboring
50-truncated gRNAs (tru-gRNAs),8 (2) ratio-
nally designed high-specificity SpCas9 vari-
ants,9,10 (3) offset RGN pairs containing558 Molecular Therapy: Nucleic Acids Vol. 8 S
This is an open access article under the Cnicking SpCas9 mutants,11,12 and (4) repur-
posing of RGNs with longer PAMs, such
as those from the S. aureus CRISPR/Cas9
system.3,4 An overview of these approaches
is presented in Figure S1.
Previous studies have shown a preferential
interaction between SpCas9-based RGNs
and genomic regions with euchromatic signa-
tures.13–17 Recently, by using cellular models
based on the conditional recruitment of
epigenetic remodeling complexes to isogenic
target sequences, our laboratory, and that of
others, have demonstrated that the activity
of conventional programmable nucleases,
including RGNs, can be significantly hin-
dered by compact heterochromatin in living
cells.18,19 However, so far, the extent to which
high-specificity CRISPR/Cas9 nuclease stra-
tegies are affected by higher-order chromatin
topologies remains to be determined.
Hence, here, we sought to investigate and
compare the impact that epigenetically regu-
lated three-dimensional chromatin “con-
formers” have on the performance of the
aforementioned high-specificity genome
editing principles (Figure S1). In these
experiments, we deployed complemen-
tary loss-of-function and gain-of-function
cellular systems in which the euchromatic
and heterochromatic statuses of isogenic
target sequences are controlled by doxycy-
cline (Dox).18 These systems, based on
clonal HEK.EGFPTetO.KRAB and polyclonal
HER.TLRTetO.KRAB cell lines, permit the
measurement of the frequencies of targeted
DSBs made by different programmable nu-
cleases through the quantification of EGFP
and mCherry+ cells,18,20 respectively, gener-
ated after NHEJ-mediated DSB repair (for
details, see Figure 1A). In brief, reporter cells
cultured without Dox (heterochromatic
target sites; high H3K9me3/low H3Ac) or
with Dox (euchromatic target sites; high
H3Ac/low H3K9me3) are exposed to
different programmable nuclease combina-
tions.18 After the action of the programmable
nucleases takes place, all cultures receive Dox
to allow for transgene expression and quanti-
fication of gene editing events (Figure 1A).
We started by comparing site-specific DSB
formation by RGNs containing full-lengtheptember 2017 ª 2017 The Author(s).
C BY-NC-ND license (http://creativecommons.org/gRNAs (FL-gRNAs) or Tru-gRNAs at
euchromatic (“open”) versus heterochro-
matic (“closed”) target sequences. The former
gRNAs have canonical, 20-mer spacers; the
latter display shorter, mostly 18-mer to
17-mer spacers.8 The reduced DNA-binding
energies of Tru-gRNAs is thought to cause
the preferential binding of the respective
SpCas9 partner to fully complementary
target DNA (Figure S1B).8 Gene editing
experiments were initiated by transfecting
HEK.EGFPTetO.KRAB cells, cultured in the
presence of Dox or on its absence, with plas-
mids encoding sets of SpCas9:FL-gRNA or
SpCas9:Tru-gRNA complexes targeting five
different positions along the EGFPORF (Fig-
ure S2). After the action of the various RGN
complexes had taken place, Dox was added
to the different cell cultures for flow cytomet-
ric quantification of targeted gene knockout
levels. We found that, independently of their
lengths, the various RGNs had similar chro-
matin impact indexes (Figure 1B), as defined
by the ratios between the frequencies of DSB
formation at euchromatic versus heterochro-
matic target sites (Figure S3). Hence, despite
their predicted lower DNA-binding energies,
derived from a reduced Watson and Crick
base-pairing potential, RGNs with Tru-
gRNAs were hindered by heterochromatin
to approximately the same extent as those
harboring standard FL-gRNAs.
The recognition of the PAM by the PID
domain of SpCas9 is the first event leading
to targeted DNA cleavage.21 After this initial
genomic DNA interrogation, local double
helix melting permits the nucleation of
gRNA-DNA hybridization and subsequent
R-loop expansion along a PAM-proximal to
PAM-distal direction (i.e., 30/50). Finally,
full-length heteroduplex formation between
unwound DNA and gRNA sequences trig-
gers phosphodiester bond hydrolysis on
both strands through a concerted, PAM-
dependent, allosteric activation of SpCas9’s
HNH and RuvC nuclease domains.21 Based
on this series of events, our data (Figure 1B)
indicate that, once a catalytically competent
RGN complex manages to engage a hetero-
chromatic PAM sequence, the epigenetic
barrier has, for themost part, been overcome,
with the length of the gRNA posing no
significant limitations to the subsequentlicenses/by-nc-nd/4.0/).
(legend on next page)
www.moleculartherapy.org
Letter to the Editor
Molecular Therapy: Nucleic Acids Vol. 8 September 2017 559
www.moleculartherapy.org
Letter to the Editoraforementioned downstream processes.
As corollary, the ultimate activity of
SpCas9:gRNA complexes at specific, PAM-
defined, target sites seems to be primarily
determined by the degree of chromatin acces-
sibility rather than the extent of gRNA-DNA
hybridization at those sites. These results
bode well for using 18-mer and 17-mer
Tru-gRNAs for achieving strict target DNA
cleavage8 and possibly deploying <16-mer
Tru-gRNAs, which render RGNs catalyti-
cally inert, formultiplexing purposes. Indeed,
the combination of these shortened, <16-mer
Tru-gRNAs together with SpCas9 proteins
fused to heterologous domains can be applied
in a variety of orthogonal contexts, such as
those involving combinatorial editing and
transcriptional modulation of distinct loci
in individual cells.22,23
In a previous study, our laboratory demon-
strated that RGNs consisting of FL-
gRNAs and SpCas9-HF1 or FL-gRNAs and
eSpCas9(1.1) are hindered by heterochro-
matin18. Combining Tru-gRNAs with high-
specificity Cas9 variant SpCas9-HF1 (Klein-
stiver et al.9) or eSpCas9(1.1)10 offers the
prospect for further minimizing off-target
DSB formation (Figure S1C). Previous ex-Figure 1. Assessing the Effect of Alternative Chrom
(A) Cellular reporter systems for tracking programmable nu
panel: the binding of tTR-KRAB fusion proteins to TetO e
composed of, among others, KAP1 andHP1. The addition
in the transition of the associated DNA sequences from a c
loss-of-function system. The tTR-KRAB-expressing huma
frame EGFP reporter can be placed out of frame after inde
nuclease activity. Bottom right panel: diagram of the
TLRTetO.KRAB contain a Traffic Light Reporter (TLR)20 flanke
EGFPORFwith a disrupting I-SceI recognition site, can be
red fluorescent cells are those reporting sequence-spe
EGFPTetO.KRAB cells, treated and not treated with Dox, w
determined by dividing the EGFP knockout levels measur
indicated mean ± SD (n = 3 independent experiments don
Tru-gRNAs. HEK.EGFPTetO.KRAB cells, incubated in the pr
euchromatic (+Dox) and heterochromatic (Dox) target se
experiment using RGNs with FL-gRNAs (n = 2) or Tru-gR
cells, treated and not treated with Dox, were exposed to Sp
SSBs). Cell fractions with EGFP knockout (KO) alleles are
heterochromatic target sequences. HEK.EGFPTetO.KRAB c
targeted mutagenesis under both Dox regimens were de
periments (n) performed on different days. (F) Testing of du
cells, incubated in the presence and absence of Dox, recei
were determined bymCherry-directed flow cytometry. Erro
Representative flow cytometry dot plots of these experim
high-specificity RGN complexes. Scatterplot with bar, gat
560 Molecular Therapy: Nucleic Acids Vol. 8 Speriments have, however, indicated that
such Tru-gRNA-containing RGNs display
reduced on-target activities when compared
to those bearing FL-gRNAs.9,10 Results pre-
sented in Figure 1C extend these findings
to isogenic target sequences subjected to
distinct epigenetic states. In addition, our
data indicate that the compatibility between
Tru-gRNAs and eSpCas9(1.1) is higher
than that between Tru-gRNAs and SpCas9-
HF1 in that, when compared to the former,
the latter setting yielded lower gene knockout
frequencies at each of the tested PAM-
defined target sequences. Indeed, combining
SpCas9-HF1 and Tru-gRNAs with spacers a
single nucleotide shorter than 20-mer FL-
gRNAs (i.e., g11.19 and g12.19) sufficed to
abrogate RGN activity in cells subjected to
both Dox regimens, but this was not so
when applying the sameTru-gRNAs together
with eSpCas9(1.1) (Figure 1C, left graph).
Additional gene editing experiments using
a panel of <19-mer Tru-gRNAs (i.e.,
g5.17, g10.17, g1.18 and g6.18) in HEK.
EGFPTetO.KRAB cells treated and not treated
with Dox confirmed the higher catalytic
impairment of SpCas9-HF1:Tru-gRNAcom-
plexes over their eSpCas9(1.1):Tru-gRNA
counterparts (Figure 1C, right graph).atin Topologies on High-Specificity CRISPR/Cas9 Nu
clease-induced DSB formation at isogenic target sequenc
lements triggers heterochromatin spread after the recruitm
of doxycycline (Dox) alters the tTR-KRAB conformation, pre
ompact/heterochromatic into a relaxed/euchromatic state.
n embryonic kidney cells HEK.EGFPTetO.KRAB harbor a TetO
l formation by NHEJ-mediated repair of site-specific DSBs
HER.TLRTetO.KRAB gain-of-function system. The tTR-KR
d by TetO elements (TLRTetO).18 In this construct, an out-of
placed in-frame after indel formation by NHEJ-mediated rep
cific nuclease activity. (B) Chromatin impact indexes of
ere exposed to SpCas9 together with the indicated gRN
ed at euchromatic by those gauged at heterochromatic co
e on different days). (C) Testing the impact of chromatin on
esence and in the absence of Dox, received the indicated
quences were quantified by EGFP-directed flow cytometr
NAs (n = 6) (D) Validation of HEK.EGFPTetO.KRAB cells for a
Cas9 and single gRNAs (DSBs) or SpCas9 nicking mutant
indicated in the flow cytometry histograms. (E) Screening
ells, treated and not treated with Dox, were exposed to th
termined by EGFP-directed flow cytometry. Error bars indi
al RGN nicking complexes on the gain-of-function reporter
ved the indicated dual RGN “nickases”. The frequencies of D
r bars indicatemean ±SEM. Aminimumof two and amaxim
ents are presented below each graph. (G) Comparison of
hers the datasets obtained from gene editing experiments
eptember 2017Offset gRNA pairs addressing SpCas9
“nickases” to oppositeDNAstrands guarantee
that DSBs are, for the most part, restricted to
the bipartite target site after the local coordi-
nated formation of SSBs (Figure S1D). Indeed,
specificity gains between 200-fold to >1,500-
fold have been reported for this dual RGN
nicking strategy.12 Gene editing experiments
with two gRNAs (i.e., g2.20 and g3.21), whose
target sequences partially overlap (Figure S2),
were individually combined with wild-type
SpCas9 (controls) or mixed together with
SpCas9D10A or with SpCas9H840A. These ex-
periments validatedHEK.EGFPTetO.KRAB cells
as a readout system for assessing the impact of
chromatin on dual RGN “nickases” (Fig-
ure 1D). Albeit dependent on two different
gRNAs, dual RGN “nickases” display a
higher theoretical coverage of the genomic
landscape when compared to that of conven-
tional RGNs and other dimeric programma-
ble nucleases, such as zinc-finger nucleases.5
This stems from the fact that dual RGN
“nickases” are compatible with a broad range
of DNA spacing between the target sites of
their individual members (i.e., about –4-bp
to +100-bp), which, in turn, increases the
chances for locating suitable PAMs. Hence,
to exploit this feature, in subsequent genecleases Based on SpCas9 Proteins
es possessing different chromatin conformations. Left
ent of endogenous epigenetic remodeling complexes
venting its interaction with the TetO elements, resulting
Top right panel: schematics of the HEK.EGFPTetO.KRAB
-flanked EGFP expression unit. In this construct, an in-
. Thus, non-fluorescent cells report sequence-specific
AB-expressing human embryonic retinoblasts HER.
-framemCherry ORF linked to a T2A sequence and an
air of targeted DSBs. Hence, in this case, the resulting
RGNs with full-length and truncated gRNAs. HEK.
As. The chromatin impact index for each RGN was
nditions (i.e., +Dox and –Dox, respectively). Error bars
RGNs consisting of high-specificity Cas9 variants and
nuclease-gRNA pairs. Targeted mutagenesis levels at
y. The bars in both graphs correspond to an individual
ssessing paired RGN “nickases”. HEK.EGFPTetO.KRAB
s together with two partially overlapping gRNAs (paired
dual RGN “nickase” activities at euchromatic versus
e specified dual RGN “nickases”. The frequencies of
cate mean ± SEM, corresponding to independent ex-
system. HER.TLRTetO.KRAB and control HER.TLRKRAB
SB-induced ORF correction under both Dox regimens
um of four independent experiments were carried out.
chromatin impact indexes between conventional and
carried out in HEK.EGFPTetO.KRAB cells.
Figure 2. Assessing the Effect of Alternative Chromatin Conformations on CRISPR/Cas9 Nucleases
Based on SaCas9 Proteins
(A) Target sequences of RGNs consisting of SaCas9:gRNA or SpCas9:gRNA complexes. The sequences
complementary to the S. aureus and S. pyogenes gRNAs are indicated underneath the green and orange arrows,
respectively. The sequences corresponding to the PAMs of S. aureus and S. pyogenes RGNs are highlighted by
green and orange boxes, respectively. (B) Testing the effect of chromatin on RGNs harboring SaCas9,
SaCas9KKH, or SpCas9. HEK.EGFPTetO.KRAB cells, incubated in the presence and absence of Dox, received the
indicated nuclease-gRNA pairs. Targeted mutagenesis levels at euchromatic (+Dox) and heterochromatic (Dox)
target sequences were quantified by EGFP-directed flow cytometry. Error bars correspond to mean ± SD (n = 3
independent experiments performed on different days). (C) Representative flow cytometry dot plots of
HEK.EGFPTetO.KRAB cells treated with the indicated experimental conditions.
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EGFPTetO.KRAB cells, we focused on using
sets of gRNA pairs (i.e. g8.20/g6.20, g8.20/
g9.20, and g8.20/g7.20) with non-overlap-
ping target sequences (Figure S2). Flow cyto-
metric quantification of EGFP cells gener-
ated in HEK.EGFPTetO.KRAB cultures after
NHEJ-mediated DSB repair revealed that
dual RGN “nickases” were significantly
impaired at heterochromatic target sites (Fig-
ure 1E). This was independent of the nicking
SpCas9 mutant used and, therefore, inde-
pendent of the type of single-stranded
DNA overhangs generated (Figure 1E).
Similar results were obtained after flow cyto-
metric quantification of mCherry+ cells in
HER.TLRTetO.KRAB cultures subjected to
both Dox regimens and exposed to different
gRNA pairs (i.e., g2.20/gI-SceI and g2.21/
gI-SceI) combined with each of the two nick-
ing SpCas9 mutants (Figure 1F and Fig-
ure S4). Importantly, there were no signifi-
cant Dox-dependent differences in the
frequencies of mCherry+ cells in control,
TetO, HER.TLRKRAB cultures subjected to
the same experimental conditions that had
been applied to HER.TLRTetO.KRAB cultures.
Taken together, these experiments show
that, in contrast to RGNs containing Tru-
gRNAs, dual RGN “nickases” are signifi-
cantly more affected by heterochromatin
than conventional RGNs (Figure 1G). We
speculate that, when heterochromatinized,
the intervening sequences separating the
two opposite SSBs made by dual RGN
“nickases” might become more resistant to
double helix denaturation when compared
to their euchromatinized isogenic counter-
parts. Interestingly, of the two types of dual
RGN “nickases,” those based on SpCas9D10A
are the least hindered by heterochromatin.
SpCas9D10A cuts the DNA strand comple-
mentary to the gRNA, whereas SpCas9H840A
cleaves the non-complementary strand.
Moreover, in contrast to SpCas9D10A,
SpCas9H840A has 30 to 50 exonuclease activ-
ity.2 Whether these or other biochemical
traits underlie the observed differential
impact of heterochromatin on the activity
of these dual RGN “nickases” will be worthy
of further investigation.
The relatively small size of the SaCas9
coding sequence (3.3 Kb) permits itsNucleic Acids Vol. 8 September 2017 561
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ments and gRNA expression units, into viral
vector particles with limited packaging ca-
pacity, such as those of commonly used ad-
eno-associated viral vectors.3 In addition,
SaCas9-based RGNs increase gene editing
versatility by permitting orthogonal (epi)
genetic manipulations and potentially offer
a higher degree of target site specificity
owing to their extended spacer and PAM se-
quences. Recently, a molecular evolution
strategy led to the selection of a SaCas9
variant with an expanded targeting range,
i.e., SaCas9KKH (PAM = NNNRRT instead
of NNGRRT), further increasing the versa-
tility of SaCas9-based RGNs.4 As of yet,
the impact of chromatin on these new
gene editing tools has not been studied.
Therefore, we next carried out gene editing
experiments in HEK.EGFPTetO.KRAB cells
using SaCas9:gRNA and SaCas9KKH:gRNA
complexes targeting three different EGFP
sites embedded in euchromatin or hetero-
chromatin (Figure 2A). As references, we
also targeted each of these target sequences
with prototypic SpCas9:gRNA complexes
(Figure 2A). Results presented in Figures
2B and 2C reveal that the SaCas9 RGNs
were clearly hindered by heterochromatin.
In fact, in contrast to SpCas9 RGNs, at het-
erochromatin, SaCas9 RGNs yielded fre-
quencies of EGFP knockout that were at or
only slightly above background levels.
We conclude that the higher-order chro-
matin environment is an important param-
eter to take into consideration while select-
ing and designing the tools and strategies
underlying precise genome editing based
on high-specificity CRISPR/Cas9 nuclease
complexes.
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